|
Asthma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We tested whether this potentially functional allele in the NOS2 gene influences the development of atopy and asthma.
|
11692109 |
2001 |
|
Asthma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to investigate the association of iNOS promoter gene polymorphisms and FeNO levels in Japanese asthmatics before the introduction of asthma treatment.
|
27021121 |
2016 |
|
Asthma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Physician-diagnosed asthma and acute chest syndrome: associations with NOS polymorphisms.
|
17351927 |
2007 |
|
Asthma
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
(CCTTT)n polymorphism of NOS2A in nasal polyposis and asthma: a case-control study.
|
18714530 |
2008 |
|
Asthma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In a cohort of 5912 adults 25-75 years of age, we investigated the relationship between NOS2 haplotypes and FENO, and effect modification by asthma.
|
24729625 |
2014 |
|
Asthma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
To investigate the association of inducible nitric oxide synthases (iNOS) gene repeat polymorphisms with asthma.
|
17189532 |
2007 |
|
Asthma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Neither NOS2 nor NOS3 variants showed any association with asthma nor IgE levels.
|
10673365 |
2000 |
|
Asthma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
(CCTTT)n polymorphism of NOS2A in nasal polyposis and asthma: a case-control study.
|
18714530 |
2008 |
|
Asthma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our findings suggest that inducible NOS can play a role in atopic disorders, and several polymorphisms in its gene may be important for asthma protection or susceptibility.
|
17177683 |
2006 |
|
Asthma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The objective of this project was to evaluate the association of NOS polymorphisms and environmental exposures with FeNO levels among children with asthma.
|
19603529 |
2009 |
|
Asthma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The association of a NOS2A promoter haplotype with FeNO varied significantly by rs3742879 genotypes and by asthma.
|
21039601 |
2011 |
|
Asthma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In addition, a significant association was found when the (CCTTT) repetition of the NOS2A gene was present more than 14 times in patients with NP and asthma (P = .034), in patients with polyposis and intolerance to nonsteroidal anti-inflammatory drugs (P = .009), and in patients with the aspirin triad (P = .005).
|
23101307 |
2012 |
|
Asthma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Arginases have been proposed to contribute to asthma pathogenesis by limiting the arginine substrate available to NOS enzymes, but expression of any of these enzymes has not been extensively studied in primary human cells.
|
18384429 |
2008 |
|
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We evaluated dietary factors associated with oxidative balance, DDIT4 (one SNP), FLT1 (35 SNPs), HIF1A (four SNPs), KDR (19 SNPs), MPO (one SNP), NOS2A (15 SNPs), TEK (40 SNPs) and VEGFA (eight SNPs) and breast cancer risk among Hispanic (2,111 cases and 2,597 controls) and non-Hispanic white (1,481 cases and 1,586 controls) women in the Breast Cancer Health Disparities Study.
|
23832257 |
2014 |
|
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Evaluation of a multi-functional nanocarrier for targeted breast cancer iNOS gene therapy.
|
21134429 |
2011 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
We aimed to comprehensively investigate which NOS gene variants are most strongly associated with coronary heart disease (CHD) and hypertension, using a set of tagging SNPs with good coverage across the 3 genes.
|
24713495 |
2014 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
However, haplotype analysis of rs2779249 and rs2297518 revealed that individuals having haplotype H3 which combines both A alleles (CA-GA, 19.7% of individuals) was more commonly found in the hypertensive group than in the normotensive group (OR = 2.01; CI = 1.29-3.12; P = 0.002).In conclusion, there was a significant association between iNOS genetic variant (rs2779249) and hypertension in the genetically homogenous Finnish population.
|
26579803 |
2015 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
While genetic polymorphisms affect iNOS expression, it is not known whether iNOS gene polymorphisms affect the susceptibility to hypertension and the responses to antihypertensive therapy.
|
23266817 |
2013 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
BEFREE |
The aim of this study was to investigate the association between variant in the human iNOS gene and susceptibility to hypertension in Chinese Han.
|
19402223 |
2009 |
|
Hypertensive disease
|
0.600 |
GeneticVariation
|
group |
LHGDN |
Relationship of eNOS gene variants to diseases that have in common an endothelial cell dysfunction.
|
15784171 |
2005 |
|
Sepsis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Sepsis independently associated with HF, increased NOx, peripheral neutrophils, and fibrinogen levels, decreased prothrombin and the presence of the NOS3 (E298D) and NOS2A (exon 22) SNPs.
|
25239655 |
2014 |
|
Sepsis
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In this study, we assessed whether SNPs within NOS2 gene were associated with severity of sepsis in Chinese populations.
|
23192595 |
2013 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.570 |
GeneticVariation
|
disease |
BEFREE |
The allele-C and genotype-TC of NOS2 rs2779248, allele-A and genotype-GA of NOS2 rs1137933 and genotype-AA of NOS3 rs3918188 genetic polymorphisms might be the risk factors for increasing the susceptibility to T2DM.
|
27192959 |
2016 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.570 |
GeneticVariation
|
disease |
BEFREE |
Genetic variations in the NOS2 gene promoter and TLR4 coding sequence may lead to deleterious and protective effects, respectively, arising from altered function of the innate immune system in patients with T2DM.
|
19395279 |
2010 |